Most Favored Nations rule for drug pricing: Gone, but not forgotten
The Centers for Medicare and Medicaid Services late Friday proposed to rescind another Trump-era drug pricing rule, this time for a rule that sought to lower prescription drug costs by paying no more for high-cost Medicare Part B drugs than the lowest price in some similar international markets.
The so-called Most Favored Nation Model interim final rule, which drugmakers decried as price controls and Trump’s HHS pledged would save $85 billion over seven years, never got off the ground. Three different lawsuits, including one from Regeneron (Part B spends more on Regeneron’s Eylea than any other drug), were filed to stop the rule from taking effect. The suits resulted in such a halt, meaning the rule was never implemented.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.